Legal & General Group Plc lessened its holdings in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 5.1% during the fourth quarter, HoldingsChannel.com reports. The firm owned 1,074,265 shares of the medical research company’s stock after selling 58,039 shares during the period. Legal & General Group Plc’s holdings in IQVIA were worth $242,150,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. lifted its position in shares of IQVIA by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock worth $4,429,426,000 after purchasing an additional 159,899 shares in the last quarter. Alliancebernstein L.P. lifted its position in shares of IQVIA by 1.2% in the third quarter. Alliancebernstein L.P. now owns 3,597,572 shares of the medical research company’s stock worth $683,323,000 after purchasing an additional 41,643 shares in the last quarter. Boston Partners bought a new stake in shares of IQVIA in the third quarter worth $676,698,000. Artisan Partners Limited Partnership raised its position in IQVIA by 4.9% during the third quarter. Artisan Partners Limited Partnership now owns 3,433,957 shares of the medical research company’s stock worth $652,246,000 after acquiring an additional 161,085 shares in the last quarter. Finally, Invesco Ltd. lifted its stake in IQVIA by 15.3% in the third quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company’s stock valued at $526,891,000 after acquiring an additional 367,204 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.
Analyst Ratings Changes
A number of brokerages have recently commented on IQV. Evercore reissued an “outperform” rating and issued a $185.00 price objective on shares of IQVIA in a research report on Wednesday, April 8th. Stifel Nicolaus decreased their price objective on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a research report on Friday, February 6th. BMO Capital Markets set a $250.00 price objective on shares of IQVIA in a research report on Friday, February 6th. Mizuho set a $215.00 price objective on shares of IQVIA in a research report on Monday, February 23rd. Finally, Jefferies Financial Group decreased their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $225.69.
IQVIA Price Performance
NYSE:IQV opened at $165.97 on Thursday. IQVIA Holdings Inc. has a one year low of $136.41 and a one year high of $247.04. The company has a market cap of $27.70 billion, a P/E ratio of 20.57, a P/E/G ratio of 1.55 and a beta of 1.18. The firm’s fifty day moving average price is $169.80 and its two-hundred day moving average price is $196.48. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75.
IQVIA (NYSE:IQV – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. During the same period in the previous year, the company earned $2.70 earnings per share. The company’s quarterly revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities analysts expect that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.
IQVIA declared that its board has approved a stock buyback plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board of directors believes its shares are undervalued.
IQVIA Company Profile
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
Featured Stories
- Five stocks we like better than IQVIA
- Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak
- TeraWulf Bets on Power Infrastructure to Lead AI Build-Out
- Amazon’s Alexa for Shopping Strengthens an Already Strong Bull Case
- Keysight: The AI and Defense Stock Seeing Big Price Target Boosts
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
